Acute myeloid leukaemia (AML) is a haematopoietic stem cell disorder, that is characterized
by the clonal expansion of myeloid blasts and suppression of normal haematopoiesis. The …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the
past 3–4 decades with generally poor outcomes, especially in elderly populations unfit for …

The therapeutic approach for acute myeloid leukemia (AML) remains challenging, since
over the last four decades a stagnation in standard cytotoxic treatment has been observed …

Abstract Purpose of Review The extensive genomic characterization of acute myeloid
leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We …

Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for
patients with AML was limited to induction chemotherapy with cytarabine and anthracycline …

The acute myeloid leukemia (AML) treatment landscape has changed substantially since
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …

Introduction: The prognosis of acute myeloid leukemia (AML) is improved in the last two
decades, even though induction and consolidation chemotherapy has not involved new …

Opinion statement The treatment of acute myeloid leukemia (AML) has evolved considerably
over the past several years. Advances in the field have historically benefited younger …